Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The NEMO Trial (NRAS Melanoma and MEK Inhibitor):A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma

NCT01763164 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01763164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01763164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The NEMO Trial (NRAS Melanoma and MEK Inhibitor):A Randomized Phase III, Open Label, Multicenter, Two-arm Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Patients With Advanced Unresectable or Metastatic NRAS Mutation-positive Melanoma
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
July 12, 2013
Completion date
June 4, 2019
Enrollment
402 (actual)
Sites
229

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic or unresectable cutaneous melanoma